Maternal Serum Vascular Endothelial Growth Factor in Patients with Preeclampsia

Elsokkary, M; El-Refaie, Tamer A.; Mostafa, Noha Bassiouny Hassan; Elaassar, Mona Mohamed Soliman

doi:10.12816/0040112

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to our results, some studies observed increased VEGF serum levels among women presenting with PE [ 29 , 32 ]. This may be attributed to inherent population differences, different methodological approaches, and the fact that platelets release VEGF during the clotting process, hence increasing its levels in serum samples.…”

Section: Discussioncontrasting

confidence: 99%

“…This makes prevention, prediction, early detection and management a challenge. Angiogenic factors constitute a list of biomarkers suggested for their potential use in the management of PE in different populations [ 16 , 29 – 31 ]. In this study, we set out to determine the circulating levels of angiogenic factors (sFlt1, VEGF, and PlGF) and their association with PE among women in a Ugandan population, and to determine their ability to diagnose PE.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating levels of angiogenic factors and their association with preeclampsia among pregnant women at Mulago National Referral Hospital in Uganda

et al. 2021

View full text Add to dashboard Cite

Preeclampsia (PE) is a major cause of maternal and new-born morbidity and mortality. Angiogenic factors contribute a major role in the vascular dysfunction associated with PE. We investigated the circulating levels of vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and soluble Feline McDonough Sarcoma (fms)—like tyrosine kinase-1 (sFlt1), their association with PE and diagnostic performance of disease among pregnant women in Uganda. Using a case-control study design, 106 women with PE and 106 with normal pregnancy were enrolled. Demographic and clinical characteristics, and anticoagulated blood samples were collected from participants. Plasma VEGF, PlGF and sFlt1 levels were measured using Luminex and enzyme linked immunosorbent assays (ELISA). Conditional logistic regression was used to explore association of angiogenic factors with PE and receiver operating characteristic analysis was performed to investigate PE diagnostic performance. Levels of VEGF and PIGF were significantly lower in cases compared to controls (VEGF: median = 0.71 pg/ml (IQR = 0.38–1.11) Vs 1.20 pg/ml (0.64–1.91), p-value<0.001 and PlGF: 2.20 pg/ml (1.08–5.86) Vs 84.62 pg/ml (34.00–154.45), p-value<0.001). Plasma levels of sFlt1 were significantly higher in cases than controls (median = 141.13 (71.76–227.10) x103 pg/ml Vs 19.86 (14.20–29.37) x103 pg/ml). Increasing sFlt1 levels were associated with increased likelihood of PE (aOR = 4.73; 95% CI, 1.18–19.01; p-value = 0.0287). The sFlt1/PlGF ratio and sFlt1 had a better performance for diagnosis of PE, with AUC = 0.95 (95% CI, 0.93–0.98) followed by PlGF with AUC = 0.94 (95% CI, 0.91–0.97). Therefore, sFlt1, sFlt1/PlGF ratio and PlGF are potential candidates for incorporation into algorithms for PE diagnosis in the Ugandan population.

show abstract

Section: Discussioncontrasting

confidence: 99%